150 related articles for article (PubMed ID: 18997387)
1. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae.
Rothstein DM; Suchland RJ; Xia M; Murphy CK; Stamm WE
J Antibiot (Tokyo); 2008 Aug; 61(8):489-95. PubMed ID: 18997387
[TBL] [Abstract][Full Text] [Related]
2. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
[TBL] [Abstract][Full Text] [Related]
3. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
[TBL] [Abstract][Full Text] [Related]
5. Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections.
Rothstein DM; van Duzer J; Sternlicht A; Gilman SC
Arch Pharm (Weinheim); 2007 Oct; 340(10):517-29. PubMed ID: 17912677
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.
Rothstein DM; Farquhar RS; Sirokman K; Sondergaard KL; Hazlett C; Doye AA; Gwathmey JK; Mullin S; van Duzer J; Murphy CK
Antimicrob Agents Chemother; 2006 Nov; 50(11):3658-64. PubMed ID: 16940074
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of drug-resistance to rifampin and rpoB gene sequence analysis of Mycobacterium abscessus].
Sha W; Weng XH; Xiao HP; He GJ
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Sep; 26(9):544-7. PubMed ID: 14521758
[TBL] [Abstract][Full Text] [Related]
9. Development potential of rifalazil and other benzoxazinorifamycins.
Rothstein DM; Shalish C; Murphy CK; Sternlicht A; Campbell LA
Expert Opin Investig Drugs; 2006 Jun; 15(6):603-23. PubMed ID: 16732714
[TBL] [Abstract][Full Text] [Related]
10. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
11. rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.
Achour W; Guenni O; Fines M; Leclercq R; Ben Hassen A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2757-9. PubMed ID: 15215145
[TBL] [Abstract][Full Text] [Related]
12. Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection.
Suchland RJ; Brown K; Rothstein DM; Stamm WE
Antimicrob Agents Chemother; 2006 Feb; 50(2):439-44. PubMed ID: 16436694
[TBL] [Abstract][Full Text] [Related]
13. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
[TBL] [Abstract][Full Text] [Related]
14. Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.
Rupp J; Gebert A; Solbach W; Maass M
Antimicrob Agents Chemother; 2005 Jan; 49(1):406-7. PubMed ID: 15616321
[TBL] [Abstract][Full Text] [Related]
15. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates.
Saribaş Z; Kocagöz T; Alp A; Günalp A
J Clin Microbiol; 2003 Feb; 41(2):816-8. PubMed ID: 12574290
[TBL] [Abstract][Full Text] [Related]
16. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
[TBL] [Abstract][Full Text] [Related]
17. A newly identified 191A/C mutation in the Rv2629 gene that was significantly associated with rifampin resistance in Mycobacterium tuberculosis.
Wang Q; Yue J; Zhang L; Xu Y; Chen J; Zhang M; Zhu B; Wang H; Wang H
J Proteome Res; 2007 Dec; 6(12):4564-71. PubMed ID: 17970586
[TBL] [Abstract][Full Text] [Related]
18. Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization.
Rothstein DM; Mullin S; Sirokman K; Söndergaard KL; Johnson S; Gwathmey JK; van Duzer J; Murphy CK
J Antibiot (Tokyo); 2008 Aug; 61(8):485-8. PubMed ID: 18997386
[TBL] [Abstract][Full Text] [Related]
19. Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
Osburne MS; Murphy CK; Rothstein DM
J Antibiot (Tokyo); 2006 May; 59(5):303-8. PubMed ID: 16883781
[TBL] [Abstract][Full Text] [Related]
20. Rifampicin resistance and its fitness cost in Enterococcus faecium.
Enne VI; Delsol AA; Roe JM; Bennett PM
J Antimicrob Chemother; 2004 Feb; 53(2):203-7. PubMed ID: 14688044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
